Literature DB >> 20798067

Neuroendocrine-type prostatic adenocarcinoma with microsatellite instability in a patient with lynch syndrome.

David G Wagner1, Zoran Gatalica, Henry T Lynch, Shane Kohl, Sonny L Johansson, Subodh M Lele.   

Abstract

Lynch syndrome is an autosomal-dominant cancer syndrome that can be identified with microsatellite instability molecular tests or immunohistochemical stains on pathologic material from patients who meet the Amsterdam Criteria II. The development of prostatic carcinoma in situ or invasive small cell carcinoma (SCC) of the prostate has not been previously reported in a patient with this syndrome. In this report, an 87-year-old White man with the Lynch syndrome had a prostate biopsy that revealed a mixed high-grade conventional adenocarcinoma and SCC of the prostate with high-grade prostatic intraepithelial neoplasia of the small cell neuroendocrine-type (HGPIN-NE), all showing MSH2 microsatellite instability and loss of MSH2 expression, a finding not previously published. These findings suggest that HGPIN-NE is a precursor of invasive SCC and also that prostatic SCC can develop in a patient with the Lynch syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20798067     DOI: 10.1177/1066896910379406

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  9 in total

1.  Is prostate cancer a Lynch syndrome cancer?

Authors:  Aung Ko Win
Journal:  Asian J Androl       Date:  2013-07-01       Impact factor: 3.285

2.  A molecularly confirmed neuroendocrine tumor resulting from Lynch Syndrome.

Authors:  Steven Sorscher; Bikramajit Saroya
Journal:  J Gastrointest Oncol       Date:  2013-03

3.  The spectrum of urological malignancy in Lynch syndrome.

Authors:  P J Barrow; S Ingham; C O'Hara; K Green; I McIntyre; F Lalloo; J Hill; D G Evans
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

4.  High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry.

Authors:  Christophe Rosty; Michael D Walsh; Noralane M Lindor; Stephen N Thibodeau; Erin Mundt; Steven Gallinger; Melyssa Aronson; Aaron Pollett; John A Baron; Sally Pearson; Mark Clendenning; Rhiannon J Walters; Belinda N Nagler; William J Crawford; Joanne P Young; Ingrid Winship; Aung Ko Win; John L Hopper; Mark A Jenkins; Daniel D Buchanan
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

5.  Catalog of mRNA expression patterns for DNA methylating and demethylating genes in developing mouse lower urinary tract.

Authors:  Kimberly P Keil; Helene M Altmann; Vatsal Mehta; Lisa L Abler; Erik A Elton; Chad M Vezina
Journal:  Gene Expr Patterns       Date:  2013-08-03       Impact factor: 1.224

6.  Elevated risk of prostate cancer among men with Lynch syndrome.

Authors:  Victoria M Raymond; Bhramar Mukherjee; Fei Wang; Shu-Chen Huang; Elena M Stoffel; Fay Kastrinos; Sapna Syngal; Kathleen A Cooney; Stephen B Gruber
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

Review 7.  Cervical neuroendocrine tumor in a young female with Lynch Syndrome.

Authors:  Ibraheem Yousef; Fadi Siyam; Lester Layfield; Carl Freter; James R Sowers
Journal:  Neuro Endocrinol Lett       Date:  2014       Impact factor: 0.765

8.  Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report.

Authors:  Tsukasa Yoshida; Hiroshi Yaegashi; Ren Toriumi; Suguru Kadomoto; Hiroaki Iwamoto; Kouji Izumi; Yoshifumi Kadono; Hiroko Ikeda; Atsushi Mizokami
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

9.  Chemotherapy induced microsatellite instability and loss of heterozygosity in chromosomes 2, 5, 10, and 17 in solid tumor patients.

Authors:  Nasir Kamat; Mohammed A Khidhir; Sabir Hussain; Mouied M Alashari; Ulf Rannug
Journal:  Cancer Cell Int       Date:  2014-11-30       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.